Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Epidemiology/Health Services/Psychosocial Research

Hepatitis C Infection and Type 2 Diabetes in American-Indian Women

  1. Charlton Wilson, MD
  1. From the Centers of Excellence, Phoenix Indian Medical Center, Phoenix, Arizona
  1. Address correspondence and reprint requests to Charlton Wilson, MD, Centers of Excellence, Phoenix Indian Medical Center, 4212 N. 16th St., Phoenix, AZ 85016. E-mail: charlton.wilson{at}mail.ihs.gov
Diabetes Care 2004 Sep; 27(9): 2116-2119. https://doi.org/10.2337/diacare.27.9.2116
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE—The aim of this study was to describe the association between hepatitis C virus (HCV) infection and type 2 diabetes among a group of American-Indian women who were screened for both conditions.

RESEARCH DESIGN AND METHODS—The study population was a convenience sample of women who were receiving prenatal care. All women were systematically screened for both HCV and diabetes.

RESULTS—A total of 426 women were included in the sample. HCV infection was detected in 13 (3.1% [95% CI 1.7–5.0]) and type 2 diabetes in 22 (5.2%, [3.3–7.6]) women. Women diagnosed with type 2 diabetes were more obese and had higher serum alanine aminotransferase activity compared with women without diabetes. Four of 13 (30.8% [10.6–58.7]) HCV-infected women and 18 of 413 (4.4% [2.7–6.7]) women without evidence of HCV infection had type 2 diabetes. (odds ratio 9.8 [95% CI 2.4–34.0], Fisher’s exact test P = 0.003). In a logistic regression model, increasing age (10-year increments), obesity (by standard deviations from the mean BMI), and positive HCV status were each independently related to the diagnosis of diabetes.

CONCLUSIONS—Among American-Indian women, type 2 diabetes is more common in those with than in those without HCV infection. This association and its potential mechanisms may have clinical implications. Investigation into the mechanisms linking HCV infection to the expression of type 2 diabetes may also help to define processes that promote the development of type 2 diabetes in susceptible individuals.

  • ALT, alanine aminotransferase
  • HCV, hepatitis C virus
  • NHANES III, Third National Health and Nutrition Examination Survey
  • TNF-α, tumor necrosis factor-α

People with hepatitis C virus (HCV) infection appear to be at increased risk of developing type 2 diabetes (1–14). The impact of HCV infection on the occurrence of type 2 diabetes in American Indians, an ethnic group with high prevalence of type 2 diabetes (15), is unknown. The aim of this study was to describe the relationship of HCV infection to the presence of type 2 diabetes among a group of American-Indian women who were systematically screened for both conditions.

RESEARCH DESIGN AND METHODS

The Phoenix Indian Medical Center is an inpatient and outpatient Indian Health Service facility located in Phoenix, Arizona. Many different tribal affiliations from around the country are represented among the patient population.

The study population was a convenience sample of women who were receiving prenatal care at the medical center. Prenatal services included the routine screening for hepatitis B virus infection (16). After 1999, the laboratory panel used for screening for hepatitis B virus also included a second-generation hepatitis C antibody. All patients also received a 50-g oral glucose tolerance test during the second trimester of pregnancy, and abnormal screening tests were followed up with a 100-g glucose tolerance test (17). When clinically indicated by the presence of risk factors for diabetes, screening and diagnostic tests for diabetes were performed earlier in pregnancy. Because these women received systematic screening for both hepatitis C and diabetes, this population presented the opportunity to study the relationship between the two conditions.

Women were identified by a three-step review of the computerized hospital information system. First, 2,463 patients who had a second-generation anti-HCV antibody test between 1 October 1999 and 30 September 2000 were identified. Second, we narrowed the sample to 541 patients who had a positive urine pregnancy test within 6 months before the HCV test. Finally, the analysis was further limited to a sample of 426 of these women who had a prepregnancy weight and height recorded to calculate a BMI.

The diabetes status for each patient was further confirmed by electronic search for visits for diabetes preceding, during, and after pregnancy and by matching all 426 patients to an actively maintained Diabetes Registry maintained at the Phoenix Indian Medical Center (18). To confirm the electronic record review and the accuracy of classification, the paper medical record for each patient in the sample identified as having diabetes was reviewed in depth. The 1997 American Diabetes Association criteria for the diagnosis and classification of diabetes were applied to each case to differentiate gestational diabetes from other forms of diabetes and thereby assure a correct diagnosis of type 2 diabetes (19). None of the case subjects of type 2 diabetes had their first abnormal glucose detected during pregnancy. However, had that occurred, the case definition would have required persistence of the glucose abnormality beyond pregnancy. Thus, in this convenience study sample of women who were receiving prenatal care, the primary use of the glucose tolerance testing was to assure the absence of diabetes in those with normal results. The age at diagnosis of diabetes was determined from historical information in the medical record.

Laboratory measurements

Presence of HCV infection was assessed by testing for serum HCV-specific antibodies (anti-HCV) using a commercial enzyme-linked immunosorbent assay with confirmation by an immunoblot assay on anti-HCV+ samples to confirm HCV specificity.

Additional laboratory data

In addition, the hospital information system laboratory database was queried to identify the most recent alanine aminotransferase (ALT) value if available and if performed between 1 October 1999 and 30 September 2001.

Statistical analysis

Statistical analysis (including prevalence rates, confidence intervals, and odds ratios) were calculated using Epi-Info statistical software (Stone Mountain, GA). The statistical significance of the relationship between HCV and type 2 diabetes was determined by applying Fisher’s exact test on the results of a two-by-two table. A multiple logistic regression model was computed using SAS (Cary, NC). In the model, BMI in 10-unit increments, 10 years of age, and ALT were used. Approval for the study was obtained from the Phoenix Area Institutional Review Board.

RESULTS

The demographic and clinical characteristics of the 426 patients included in the sample are shown in Table 1. HCV infection was detected in 13 (3.1% [95% CI 1.7 −5.0]) of the 426 women in the sample. None of the women in the sample had detectable hepatitis B surface antigen. The mean age of anti-HCV+ and anti-HCV− women in this sample was not statistically different (27.0 ± 6.7 vs. 24.8 ± 5.6 years, P = 0.37). There was a trend (χ2, P = 0.13) toward an increased prevalence of anti-HCV with age when comparing women by the following age categories: 15–24 years (2.2% [0.8–4.8]), 25–34 years (3.0% [1.1–6.7]), and 35–44 years (8.3% [2.1–21.0]). Within the study time frame, 11 of 13 anti-HCV+ (84.6%) and 114 of 413 (27.6%) anti-HCV− women had a determination of serum ALT activity. The mean ALT values of anti-HCV+ and anti-HCV− women in this sample were not statistically different (37.2 ± 15.3 vs. 41.9 ± 40.9 mg/dl, P = 0.82). Among those tested, 1 (9.1%) of 11 anti-HCV+ and 13 (11.4%) of 114 anti-HCV− women had an ALT greater than the upper limit of normal value of 65 mg/dl for the clinical laboratory.

Type 2 diabetes was confirmed in 22 (5.2% [95% CI 3.3–7.6]) of the 426 women in the sample. Nine additional women had glucose abnormalities consistent with gestational diabetes and were not included in the analysis. Women diagnosed with type 2 diabetes were older than women without a diagnosis of diabetes (29.5 ± 7.1 vs. 24.7 ± 5.4 years, P = 0.0001). There was an increased prevalence of diabetes with age (χ2 for trend, P = 0.001) when comparing women by age category: 15–24 years (2.2% [0.8–4.8]), 25–34 years (6.7% [3.6–11.4]), and 35–44 years (16.7% [7.0–31.5]). Women with diabetes were more obese, as measured by BMI (35.4 ± 3.0 vs. 28.5 ± 6.6 kg/m2, P = 0.000002), and had higher serum ALT activity (49.2 ± 24.4 vs. 44.4 ± 41.1 mg/dl, Kruskall-Wallis P = 0.01) compared with women without diabetes, but the difference in ALT did not persist after adjustment for BMI.

The association of HCV infection and type 2 diabetes is demonstrated in Fig. 1. Diabetes was present in 4 of 13 (30.8% [95% CI 10.6–58.7]) HCV-infected women and in 18 of 413 (4.4% [2.7–6.7]) women without evidence of HCV infection (odds ratio 9.8 [95% CI 2.4–34.0], Fisher’s exact test P = 0.003). In a logistic regression model, increasing age (10-year increments), obesity (by standard deviations from the mean BMI), and positive HCV status were each independently related to the diagnosis of diabetes. The addition of serum ALT activity did not affect the model (Table 2).

The relative prevalence of type 2 diabetes among women with and without hepatitis C infection, and therefore potentially attributable to hepatitis C infection, is 0.264. Assuming these pregnant women are representative of other members of the population (i.e., nonpregnant women, men, and all other age-groups), a prevalence of HCV of 0.03 results in a population risk of diabetes attributable to HCV infection of 0.264 × 0.03 or 0.008.

CONCLUSIONS

Among American-Indian women, type 2 diabetes occurs more often in women who test positive for HCV infection than in those who test negative. The association between type 2 diabetes and HCV infection persisted in logistic regression analyses that included age and BMI. This finding supports the association of HCV infection with type 2 diabetes.

Whereas this was a retrospective study of a convenience sample of women who were undergoing routine prenatal care, the systematic screening process for both HCV and diabetes help to limit potential selection bias. Also, because sample was created from women receiving routine prenatal care as opposed to specialty evaluation for disease, the findings will likely be generalizable to the greater patient population.

HCV is the most common chronic blood-borne infection in the U.S. (20,21). The prevalence of HCV in an American-Indian population has not previously been reported. However, the 3.1% prevalence of HCV infection in this sample of women was within the range reported for the general U.S. population. Specifically, the overall U.S. prevalence among participants in the Third National Health and Nutrition Examination Survey (NHANES III) from 1988–1994 was 1.8% (95% CI 1.5–2.3) but ranged from 1.5 (1.1–2.0) in non-Hispanic whites to 2.1 (1.7–2.6) in Mexican Americans, to 3.2 (2.6–4.0) in non-Hispanic blacks, and 2.9 (2.4–5.8) in other ethnic groups (22). The prevalence of HCV infection in the current study is also within the ranges reported among women being tested as a component of prenatal care from study in various countries. Among a multiethnic population of pregnant women attending an inner London obstetric department, the overall prevalence of anti-HCV reactivity was 0.8% (23). Similarly, among pregnant women in Germany, 0.8% of women were found to be anti-HCV+ (24). The prevalence of HCV infection was 1.5% among women screened during prenatal care in Brazil (25). Among pregnant women attending an inner city clinic in Philadelphia, the HCV prevalence was 4.3% (26). The highest reported prevalence of anti-HCV in a prenatal care population was in Egypt where 19% of women tested positive (27). Thus, the prevalence of HCV among pregnant American-Indian women appears to be within the wide range of rates reported in the literature.

The prevalence of type 2 diabetes in this population was also similar to other reports of American-Indian women of childbearing age (28). In the present study, consistent with many studies, both age and obesity were strongly associated with diabetes (19).

As noted, the recognition of an association between HCV infection and type 2 diabetes has been previously reported. However, this is the first report to demonstrate relationship in an American-Indian population and the first to demonstrate this association in people <40 years of age. Interestingly, the magnitude of the association between HCV infection and diabetes in the current study is similar to the magnitude of the association in high-risk subgroups from the NHANES population (8). The women in the current study are all at increased risk for diabetes because of their ethnicity, which may explain both the high odds ratio and the occurrence in young age-groups.

Several mechanisms may explain the link between HCV infection and type 2 diabetes. Hepatic steatosis and cirrhosis, both features of HCV infection, have been associated with abnormal glucose regulation (29). Steatosis in particular has been related to intracellular fat accumulation and insulin resistance, and along these lines, in Pima Indians, ALT, a marker of steatosis, is predictive of the development of type 2 diabetes (30). In the present study, these young, relatively healthy women would be unlikely to have developed cirrhosis, and the ALT values were not different between those with or without diabetes. Recent animal model evidence suggests a more direct effect of HCV infection on insulin resistance in the liver. Shintani et al. (31) used transgenic mice that specifically express the HCV core protein at high levels in hepatocytes. In these transgenic mice, elevated circulating insulin levels and islet cell hyperplasia were present before the onset of steatosis. Because hepatic tumor necrosis factor-α (TNF-α) is known to be elevated in this animal model (31) and in human HCV infection (32) and to have an effect on insulin signaling (33), the authors evaluated the role of hepatic TNF-α in affecting insulin signaling in this animal model of HCV infection. Indeed, insulin-induced tyrosine phosphorylation of IRS-1 was inhibited in the transgenic mice, and the effect was prevented by administration of anti-TNF-α antibody. Interestingly, euglycemic insulin clamp and muscle glucose uptake studies on these mice demonstrated defective insulin inhibition of hepatic glucose production but normal glucose uptake in muscle. Together, these findings suggest that expression of the HCV core protein induces hepatic insulin resistance via alterations in signaling in the insulin receptor–IRS-1 pathway and that this, along with other factors such as diet and obesity, can result in expression of the diabetic phenotype. Other pathways may also exist (29). In our retrospective study, neither measurement of TNF-α nor markers of the level of activity of HCV infection were available. Future studies should be designed to assess these pathways in humans with HCV infection and diabetes.

The transgenic mouse model and the present study may also provide clues to the prevention and clinical management of diabetes in the setting of HCV infection. In the transgenic mouse model, diabetes only developed when the mice were challenged with a high-fat diet (31). In the present analysis, BMI was associated with diabetes independently of HCV infection. Thus, weight control should continue to be a preventive and therapeutic goal. Also, because defective insulin signaling in HCV infection may be limited to the liver, pharmacologic therapy might logically be tailored to the function of this organ. The biguanide metformin acts primarily by decreasing endogenous glucose production in the liver (34). However, metformin is known to affect insulin signaling via induction of IRS-2, and whether metformin will have any preferential advantage over other commonly used medications for glycemic control in this setting is speculative.

In summary, among American-Indian women, type 2 diabetes is more common in those with than without HCV infection. This association is independent of age and BMI. Because of the low population attributable risk, prevention and treatment of hepatitis C infection is not likely to have a major public health role as a diabetes prevention effort. On the other hand, among those infected, attention to efforts known to delay or prevent the development of diabetes (35) as well as screening for and treatment of diabetes if identified seem particularly warranted. Finally, continued investigation into the mechanisms linking HCV infection to the expression of type 2 diabetes may help to define processes that promote the development of type 2 diabetes in susceptible individuals. Such findings could not only help those infected with HCV but also the large majority of people who develop diabetes by the interaction of multiple heritable and environmental factors.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

Prevalence of type 2 diabetes by HCV infection category.

View this table:
  • View inline
  • View popup
Table 1—

Sample characteristics

View this table:
  • View inline
  • View popup
Table 2—

Logistic regression model

Acknowledgments

The author thanks Drs. Doug Thoroughman and Ehab Raba and Ms. Audrey Lynch for their assistance in data collection and Dr. Robert Lindsay for his help with statistical analysis.

Footnotes

  • The opinions expressed in this report are those of the author and do not necessarily reflect the views of the Indian Health Service.

    A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted May 29, 2004.
    • Received March 12, 2004.
  • DIABETES CARE

References

  1. ↵
    Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, Tagaya T, Yamanouchi K, Ichimiya H, Sameshima Y, Kakumu S: Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 38:355–360, 2003
    OpenUrlCrossRefPubMed
  2. el-Zayadi AR, Selim OE, Hamdy H, Dabbous H, Ahdy A, Moniem SA: Association of chronic hepatitis C infection and diabetes mellitus. Trop Gastroenterol 19:141–144, 1998
    OpenUrlPubMed
  3. Knobler H, Schattner A: Association of hepatitis C and diabetes mellitus (Comment). Ann Intern Med 135:141–142, 2001
    OpenUrlPubMed
  4. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A: Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 75:355–359, 2000
    OpenUrlCrossRefPubMedWeb of Science
  5. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH: Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 26:30–33, 1998
    OpenUrlCrossRefPubMedWeb of Science
  6. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP: Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328–333, 1999
    OpenUrlCrossRefPubMedWeb of Science
  7. Mayo MJ: Extrahepatic manifestations of hepatitis C infection (Review). Am J Med Sci 325:135–148, 2003
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL: Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:50–56, 2003
    OpenUrlCrossRefPubMedWeb of Science
  9. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States (Comment). Hepatology 33:1554, 2001
    OpenUrlCrossRefPubMed
  10. Mehta SH, Strathdee SA, Thomas DL: Association between hepatitis C virus infection and diabetes mellitus (Review). Epidemiol Rev 23:302–312, 2001
    OpenUrlFREE Full Text
  11. Ryu JK, Lee SB, Hong SJ, Lee S: Association of chronic hepatitis C virus infection and diabetes mellitus in Korean patients. Korean J Intern Med 16:18–23, 2001
    OpenUrlPubMed
  12. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J: High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19:998–1000, 1996
    OpenUrlAbstract/FREE Full Text
  13. Thuluvath PJ, John PR: Association between hepatitis C, diabetes mellitus, and race: a case-control study. Am J Gastroenterol 98:438–441, 2003
    OpenUrlPubMedWeb of Science
  14. ↵
    Wang CS, Wang ST, Yao WJ, Chang TT, Chou P: Community-based study of hepatitis C virus infection and type 2 diabetes: an association affected by age and hepatitis severity status. Am J Epidemiol 158:1154–1160, 2003
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Burrows NR, Geiss LS, Engelgau MM, Acton KJ: Prevalence of diabetes among Native Americans and Alaska Natives, 1990–1997: an increasing burden. Diabetes Care 23:1786–1790, 2000
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Anonymous: Acog educational bulletin: viral hepatitis in pregnancy: number 248, July 1998 (replaces no. 174, November 1992): American College of Obstetricians and Gynecologists (Review). Int J Gynaecol Obstet 63:195–202, 1998
    OpenUrlPubMed
  17. ↵
    American Diabetes Association: Gestational diabetes mellitus. Diabetes Care 26 (Suppl. 1):S103–S105, 2003
  18. ↵
    Wilson C, Susan L, Lynch A, Saria R, Peterson D: Patients with diagnosed diabetes mellitus can be accurately identified in an Indian Health Service patient registration database. Public Health Rep 116:45–50, 2001
    OpenUrlPubMed
  19. ↵
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197, 1997
    OpenUrlFREE Full Text
  20. ↵
    Alter MJ: Hepatitis C virus infection in the United States (Review). J Hepatol 31 (Suppl. 1):88–91, 1999
  21. ↵
    Wasley A, Alter MJ: Epidemiology of hepatitis C: geographic differences and temporal trends (Review). Semin Liver Dis 20:1–16, 2000
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562, 1999
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster GR: Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut 47:277–280, 2000
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Hillemanns P, Dannecker C, Kimmig R, Hasbargen U: Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy. Acta Obstet Gynecol Scand 79:543–547, 2000
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Lima MP, Pedro RJ, Rocha MD: Prevalence and risk factors for hepatitis C virus (HCV) infection among pregnant Brazilian women. Int J Gynaecol Obstet 70:319–326, 2000
    OpenUrlCrossRefPubMed
  26. ↵
    Silverman NS, Jenkin BK, Wu C, McGillen P, Knee G: Hepatitis C virus in pregnancy: seroprevalence and risk factors for infection. Am J Obstet Gynecol 169:583–587, 1993
    OpenUrlPubMed
  27. ↵
    Kassem AS, El-nawawy AA, Massoud MN, Abou El-nazar SY, Sobhi EM: Prevalence of hepatitis C virus (HCV) infection and its vertical transmission in Egyptian pregnant women and their newborns. J Trop Pediatr 46:231–233, 2000
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Acton KJ, Burrows NR, Moore K, Querec L, Geiss LS, Engelgau MM: Trends in diabetes prevalence among American Indian and Alaska Native children, adolescents, and young adults [Erratum appears in Am J Public Health 92:1709, 2002]. Am J Public Health 92:1485–1490, 2002
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Weinman SA, Belalcazar LM: Hepatitis C: a metabolic liver disease (Review). Gastroenterology 126:917–919, 2004
    OpenUrlCrossRefPubMed
  30. ↵
    Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA: High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:1889–1895, 2002
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840–848, 2004
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N: Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 38:1384–1392, 2003
    OpenUrlPubMedWeb of Science
  33. ↵
    Hotamisligil GS: The role of Tnfα and Tnf receptors in obesity and insulin resistance (Review). J Intern Med 245:621–625, 1999
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    Gunton JE, Delhanty PJ, Takahashi S, Baxter RC: Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2 [Erratum appears in J Clin Endocrinol Metab 89:434, 2004]. J Clin Endocrinol Metab 88:1323–1332, 2003
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403, 2002
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes Care: 27 (9)

In this Issue

September 2004, 27(9)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hepatitis C Infection and Type 2 Diabetes in American-Indian Women
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
Citation Tools
Hepatitis C Infection and Type 2 Diabetes in American-Indian Women
Charlton Wilson
Diabetes Care Sep 2004, 27 (9) 2116-2119; DOI: 10.2337/diacare.27.9.2116

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Hepatitis C Infection and Type 2 Diabetes in American-Indian Women
Charlton Wilson
Diabetes Care Sep 2004, 27 (9) 2116-2119; DOI: 10.2337/diacare.27.9.2116
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Suboptimal Use of Cardioprotective Drugs in Newly Treated Elderly Individuals With Type 2 Diabetes
  • Disparities in Diabetes Care Between Smokers and Nonsmokers
  • Insulin Sensitivity and Insulin Secretion Determined by Homeostasis Model Assessment and Risk of Diabetes in a Multiethnic Cohort of Women
Show more Epidemiology/Health Services/Psychosocial Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • BMJ Open - Diabetes Research & Care
  • Standards of Medical Care in Diabetes
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2019 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.